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Background: Evaluate and compare the utility of serum folate receptor alpha (FRA) and megakaryocyte
potentiating factor (MPF) determinations relative to serum CA125, mesothelin (MSLN) and HE4 for the diagnosis of
epithelial ovarian cancer (EOC).
Methods: Electrochemiluminescent assays were developed for FRA, MSLN and MPF and used to assess the levels of
these biomarkers in 258 serum samples from ovarian cancer patients. Commercial assays for CA125 and HE4 were
run on a subset of 176 of these samples representing the serous histology. Data was analyzed by histotype, stage
and grade of disease. A comparison of the levels of the FRA, MSLN and MPF biomarkers in serum, plasma and urine
was also performed in a subset of 57 patients.
Results: Serum and plasma levels of FRA, MSLN and MPF were shown to be highly correlated between the two
matrices. Correlations between all pairs of markers in 318 serum samples were calculated and demonstrated the
highest correlation between HE4 and MPF, and the lowest between FRA and MPF. Serum levels of all markers showed
a dependence on both stage and grade of disease. A multi-marker logistic regression model was developed resulting
in an AUC=0.91 for diagnosis of serous ovarian cancer, a significant improvement over the AUC for any of the
individual markers, including CA125 (AUC=0.84).
Conclusions: FRA has significant potential as a biomarker for ovarian cancer, both as a stand-alone marker and in
combination with other known markers for EOC. The lack of correlation between the various markers analyzed in the
present study suggests that a panel of markers can aid in the detection and/or monitoring of this disease.
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In 2012, it is estimated that 22,280 women will be diag-
nosed with ovarian cancer and 15,500 will die of the dis-
ease (SEER fact sheet). Ovarian cancer is considered a
“silent killer” because of the absence of specific symp-
toms until late in the disease when 75% of the cases are
diagnosed, five year survival rates are less than 30%, and* Correspondence: doshannessy@MORPHOTEK.com
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distribution, and reproduction in any mediuma 70% recurrence rate is expected. Early diagnosis, when
the cancer is confined to the ovary, can increase the 5-
year survival rate to 90%. Because of the high fatality
rate and relatively low prevalence of the disease, a sensi-
tive and specific screening tool for asymptomatic women
is needed. As such, effective and reliable diagnostic as-
says need to be highly sensitive and specific for the
screening and detection of early stage ovarian cancer, es-
pecially in asymptomatic women.
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vated in approximately 80% of women with late-stage
ovarian cancer. It is the gold standard diagnostic marker
to detect recurrent ovarian cancer and monitor response
to treatment. However, the usefulness of CA125 as a
marker cannot be extended to diagnosis as 20% of
ovarian cancers do not express CA125 [1], and ele-
vated levels are detected in only half of early stage pa-
tients. Further, CA125 is detected in many benign
gynecological conditions and is particularly unreliable
in detecting ovarian cancer in premenopausal women
[2-5]. Additional biomarkers with high sensitivity and
specificity for detecting ovarian cancer in the early
stages of the disease are sought to complement CA125.
Two promising markers are human epididymis protein
4 (HE4) and mesothelin (MSLN). CA125, HE4 and
MSLN have been approved by the United States Food
and Drug Administration (FDA) as biomarkers for re-
current ovarian cancer (CA125 and HE4) and diagno-
sis of mesothelioma (MSLN).
Human epididymis protein 4 (HE4), normally expressed
in the epididymis, endometrial glands and respiratory tract
[6,7], is up-regulated in both early and late stage ovarian
cancer [6-9] including 90% of serous carcinoma, and
adenocarcinomas of the lung and endometrium [10,11]. It
is not expressed in mucinous carcinoma [12]. It has been
widely studied as a biomarker, alone and in combination
with CA125, for the diagnosis and monitoring of recurrent
disease as little or no expression is observed in benign
conditions [8,10,13,14]. When combined, HE4 has been
shown to increase the sensitivity and specificity over
CA125 alone [2,9,11,15], allowing for better detection of
early stage ovarian cancer [9,15]. HE4 levels have, how-
ever, been shown to increase with age [16].
Soluble mesothelin (MSLN) has a history as a biomarker
for mesothelioma diagnosis, prognosis and monitoring
[17-19]. It is a differentiating antigen derived from a pre-
cursor protein that when cleaved yields Megakaryocyte Po-
tentiating Factor (MPF), a 32 kDa excreted soluble protein
[20,21], and MSLN, a 40 kDa GPI-linked glycoprotein that
is also shed as a soluble form into the blood stream by
frameshift mutation and proteolytic cleavage [22,23].
MSLN is hypothesized to be involved in cell adhesion and
signaling [24] and to contribute to the metastasis of ovar-
ian cancer to the peritoneum by binding CA125 [25,26]. It
is highly expressed in mesothelioma, ovarian and pancre-
atic cancers and lung adenocarcinoma [7,23,24,27-29], but
only expressed normally in mesothelial cells of the periton-
eum, pericardium and pleura [27]. Like HE4, it has shown
promise in the detection of early stage ovarian cancer, es-
pecially in combination with CA125 [1,30,31]. Improve-
ments may be gained adding MSLN to a biomarker panel
with CA125 and HE4 to detect early stage disease [15,31]
although contradictory results have been reported [32,33].Levels of detection of MSLN from serum and plasma for
ovarian cancer were shown to be similar [34]. One issue
with measuring MSLN in serum is that levels can be af-
fected by conditions such as age, body mass index (BMI)
and glomerular filtration rate [16]. Less expensive, facile
screening can be achieved screening urine over serum or
plasma. It is of interest, therefore, that MSLN was detected
with more sensitivity in urine than serum for both early
stage (42% vs. 12%, respectively) and late stage (75% and
48%, respectively) disease [35].
Although the literature is sparser than that for MSLN, a
few studies have looked at MPF as a biomarker for meso-
thelioma [36], ovarian cancer [23] and pancreatic cancer
[37]. As biomarkers in mesothelioma, MSLN and MPF
have been shown to behave similarly [17-19].
Panels of biomarkers, able to cover the molecular het-
erogeneity of ovarian cancer [31,38], or specific to high
grade serous carcinoma [12], will be the most effective
way to detect early disease for fewer fatalities. To date, no
panel has been identified that can achieve the sensitivity
(>75%) and specificity (>99.6%) needed to meet the ac-
cepted criteria of no more than ten surgeries for every
case of early stage ovarian cancer identified. The most de-
sirable biomarkers to add to panels will be those expressed
early in disease, and not expressed in normal tissue.
One such biomarker is folate receptor alpha (FRA), a
glycosylphosphatidylinositol (GPI)-anchored protein in-
volved in folate transport into cells that is expressed in
breast, lung, clear cell renal, ovarian and endometrial car-
cinomas, and non-small cell lung adenocarcinoma [39-58].
FRA is expressed in a high percentage of serous ovarian
carcinomas in all stages and grades [44,46,55,59,60], and
levels of circulating FRA have been shown to be compar-
able between early and late stage disease [54,56]. Expres-
sion of FRA in normal tissues is restricted to the apical
surfaces of some polarized epithelial cells [40].
In the present work, novel, sensitive electrochemi-
luminescent assays were developed for the soluble forms
of FRA, MSLN and MPF and were evaluated in a large co-
hort of ovarian cancer patient samples. Further, the diag-
nostic utility of these markers was compared to CA125
and HE4 in a subset of serous ovarian cancer samples. Fi-
nally, a multi-marker logistic regression model was devel-
oped that demonstrates increased diagnostic performance
relative to any single marker.
Materials and methods
Patient samples and controls
Samples were obtained from various commercial ven-
dors with Institutional Review Board approvals and pa-
tient consent and were collected between 2009 and
2011. This study included serum samples from 258 ovar-
ian cancer cases, of which 215 were serous and 47 were
non-serous carcinoma (five unknown), and 60 age-
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non-serous ovarian cancer samples (endometrioid, mucin-
ous, clear cell), were from women with stage I or II tumors.
In addition, serum, plasma and urine samples were
collected from 57 women (37 with ovarian cancer and
20 without the disease as controls) to compare sample
matrices. All serum, plasma and urine samples were col-
lected by standard techniques and processed/frozen
within 30 min of collection. All samples were stored at
−80°C, and thawed and aliquotted prior to analysis. Pa-
tient demographics including date of diagnosis, histology,
stage, and age (Table 1) were obtained from the suppliers.
Biomarker assays
Antibodies and antigens
The generation and characterization of monoclonal anti-
bodies (MAbs) to FRA have been described previouslyTable 1 Characteristics of patients and controls
All histologies n=318
Variable Ovarian cancer N (%) Norm






Caucasian/White 228 (88%) 58
African American 2 (1%) 0
Asian/Pacific Islander 0 (0%) 2
Hispanic/Latino 1 (<1%) 0








Low (1) 28 (11%)






Clear cell 1 (<1%)
Other‡ 5 (2%)
†Non-serous tumors are all stages I and II.
‡2 granulosa cell carcinomas, 1 spinocellular carcinoma, 2 undefined.[61]. MAbs MN and MB [62] against MSLN were pur-
chased from Rockland Immunochemicals (Gilbertsville,
PA). MAbs MPF25 and MPF49, specific for megakaryo-
cyte potentiating factor (MPF) were obtained from Dr.
Ira Pastan (Center for Cancer Research, NCI) and have
been described previously [36]. All MAbs were murine
IgG and purified by Protein A chromatography.
Purified, recombinant human FRA and human MSLN
were the kind gift of Dr. Earl Albone (Morphotek Inc.,
Exton PA). MPF was prepared as a H6-construct and puri-
fied by metal-chelate chromatography. All antigens were
demonstrated to be >98% pure by both SDS-PAGE and
analytical SEC.
Novel electrochemiluminescence (ECL) assay
The FRA, MSLN and MPF assays all utilized ECL tech-
nology from MSD [63]. For the development of the FRASerous subset n=196





(97%) 158 (90%) 19 (95%)
(0%) 2 (1%) 0 (0%)
(3%) 0 (0%) 1 (5%)
(0%) 1 (1%) 0 (0%)
(0%) 15 (9%) 0 (0%)
NA 45 (26%) NA
NA 33 (19%) NA
NA 67 (38%) NA
NA 31 (18%) NA
NA 0 (0%) NA
NA 17 (10%) NA
NA 111 (63%) NA
NA 48 (27%) NA
NA 176 (100%) NA
NA 0 (0%) NA
NA 0 (0%) NA
NA 0 (0%) NA
NA 0 (0%) NA
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MAb pairs were selected from an unbiased screen using
recombinant protein, normal pooled plasma and normal
pooled urine. The final MAb pair was selected based on
sensitivity, specificity, physical properties, and recogni-
tion of native protein. The selection of MAb pairs for
MSLN (MN and MB) and MPF (MPF25 and MPF49)
was determined based on literature. Detection MAbs
were labeled with ruthenium (SULFO-TAGTM NHS-
Ester, Meso Scale Discovery (MSD®), Rockville, MD) and
label:protein was determined according the manufac-
turer’s instructions. The conjugation ratio was set to 20
labels per MAb for all assays.
Assay protocol
Samples (serum, plasma, urine), standards or controls were
added to wells of a 96-well plate previously coated with
capture antibody and incubated at RT for two-hours. The
Ruthenium labeled detection MAbs were diluted in assay
buffer, added to washed plates and incubated for an add-
itional two hours at RT. Plates were washed, read buffer
added and signals measured using an MSD DISCOVERY
WORKBENCH®. Optimal sample dilutions were: FRA (80-
fold dilution of urine and a 20-fold dilution of serum and
plasma), MSLN (60-fold dilution of urine and an 80-fold di-
lution of serum and plasma) and MPF (4-fold dilution of
urine and a 20-fold dilution of serum and plasma).
CA125 and HE4 measurements were performed by
Myriad RBM (Austin, TX) on a Luminex 100 instrument
on 176 serum samples from women with serous ovarian
tumors.
Statistical analyses
Pearson’s correlation coefficient was performed to deter-
mine the correlation among the various biomarkers. Pair-
wise comparisons of biomarker levels between normal
























Figure 1 Assay range and sensitivity representative calibrator curves.
lower limit of detection (LLOD) of 1.22 pg/mL, B) MSLN assay mean CV ran
CV ranged from 2-10% with an LLOD of 3.35 pg/mL.made using the Mann–Whitney U test. Receiver Operating
Characteristic (ROC) analysis was employed to determine
the performance of these markers by stage and grade of
disease. ROC Area Under the Curve (AUC) calculations
were based on 95% confidence intervals. Logistic regres-
sion models were developed and used to assess the per-
formance of a panel of biomarkers relative to CA125. All
comparisons were two-sided and a P-value ≤0.05 was con-
sidered statistically significant except where otherwise
stated. Statistical analyses were performed in MedCalc ver-
sion 12.30 (MedCalc Corp.), SPSS version 19 (IBM),
GraphPad Prism version 6.00 (GraphPad Software, Inc.)
and Microsoft Excel version 2010.
Results
ECL assay reproducibility, sensitivity and reliability
The intraday reproducibility and sensitivity of the ECL as-
says for FRA, MSLN and MPF were assessed at levels be-
tween 0.01 and 5000 pg/mL (Figure 1). Mean intraday
variability (CV) ranging from 2-16% for FRA, 3-7% for
MSLN and 2-10% for MPF were observed and demon-
strate good reproducibility for all three assays. All three as-
says also showed excellent sensitivity with lower limits of
detection (LLOD) of 1.22, 0.29 and 3.35 pg/mL for FRA,
MSLN and MPF, respectively. Representative calibrator
curves are shown in Figure 1 and each assay demonstrates
a wide dynamic range, potentially minimizing the need for
re-assay of samples with high biomarker levels.
Comparison of matrices: serum, plasma and urine
To assess the most appropriate matrix for determination
of the various biomarker levels, matched serum/plasma
pairs from 20 normal women and 37 women with ovar-
ian cancer were measured for FRA, MSLN and MPF
using the described ECL assays. As presented in Figure 2,
a high degree of concordance was observed between
serum and plasma for each of the three biomarkers, with102 103 104 105 10












N  (pg/mL) MPF  (pg/mL)
A) FRA assay mean intraday variability (CV) ranged from 2-16% with a


























































Figure 2 Correlation between measurements of the various markers in plasma and serum using ECL assays for A) FRA (r=0.98,
p<0.0001), B) MSLN (r=0.99, p<0.0001) and C) MPF (r=0.96, p<0.0001).
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slopes of 0.87-0.97, indicating that either sample type is
suitable for the determination of these markers and
there appears not to be a preferential distribution be-
tween either matrix. Based on these data, and the rela-
tive availability of samples, all subsequent analyses were
performed using serum samples.
Of interest, however, all three markers were also de-
tectable in urine samples from the same 57 individuals
noted above, indicating that urine could serve as a diag-
nostic matrix in ovarian cancer.
Diagnostic performance of FRA, MSLN and MPF in ovarian
cancer cases of multiple histologies
Using the described ECL assays, the serum levels of FRA,
MSLN and MPF were measured in samples from 258Table 2 Biomarker serum levels with clinicopathological findi
FRA (pg/mL)
N (%) Mean Median SD Range Mean
Normal 60 (19%) 341 324 122 176-696 11225
Ovarian Cancer 258†(81%) 1680 549 5870 155-42523 43002
Histotype‡
Serous 215 (83%) 1616 586 3622 155-42523 48731
Endometrioid 22 (9%) 1862 434 5333 185-24843 38595
Mucinous 15 (6%) 1047 497 2084 173-8475 20017
Stage
I 78 (30%) 1066 412 2876 162-24843 22654
II 47 (18%) 977 402 2877 164-8475 30439
III 45 (17%) 2014 775 5103 155-42523 58945
IV 45 (17%) 2811 1424 2477 241-14222 81160
Grade
Low 28 (11%) 541 449 409 185-2178 25615
High 148 (57%) 2090 653 4579 162-42523 55768
†Represents multiple histologies (see Table 1).
‡There are too few samples of other histotypes for analysis.ovarian cancers and 60 age-matched controls. Data for the
ovarian cancer samples was analyzed by histotype, stage
(AJCC) and grade of disease and is summarized in Table 2.
Serum levels of all biomarkers differed significantly between
ovarian cancer and control serum samples (Figure 3), with
P values of <0.0001, <0.0001 and 0.0006 for FRA, MSLN
and MPF, respectively. ROC curve analysis resulted in
AUCs of 0.80 (p<0.0001) for FRA and MSLN (p<0.0001)
and 0.641 (p=0.0007) for MPF (Figure 3) suggesting that
FRA and MSLN have greater potential with respect to dis-
crimination of individuals with ovarian cancer compared to
normal individuals, independent of other clinical variables.
Relative to histotype, FRA and MSLN both showed the
highest levels and most significant discrimination with
normals in the serous sub-type with p-values <0.0001.
Both endometrioid and mucinous sub-types could also bengs in ovarian cancer patients
MSLN (pg/mL) MPF(pg/mL)
Median SD Range Mean Median SD Range
10300 4280 5169-26891 1869 1681 618 910-3691
17279 61019 4274-311565 3602 2138 5994 717-72192
1681 62280 6322-311565 4275 2779 6446 717-72192
2138 64278 4274-240088 2786 1976 2887 1025-13492
14632 19736 7672-88153 1875 1636 789 1071-4354
14803 44258 4274-240088 2088 1686 1826 717-9075
15891 64662 6322-225597 2509 1807 3853 832-13492
36112 69385 6370-257344 5887 3164 8499 858-72192
19674 54307 8162-311565 4689 2196 5051 876-12882
14947 46648 4274-257344 2263 1904 1904 717-10850





Figure 3 Box plots of serum levels of A) FRA, B) MSLN and C)
MPF in healthy controls and ovarian cancer patients. Boxes
indicate the 25th to 75th percentiles. The horizontal lines within the
boxes are the median serum levels and the whiskers indicate the
minimum and maximum values. P-values indicate statistical
significance of differences between ovarian cancer cases and healthy
controls. D) ROC (blue line, FRA; brown line, MSLN; orange line, MPF)
curves showing the performance of serum biomarkers in
discrimination of healthy controls and ovarian cancer patients.
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to lower significance than the serous sub-type (Figure 4).
ROC curve analysis resulted in AUCs ranging from 0.72-
0.82 (Figure 4). MPF on the other hand was significantly
elevated only in the serous histotype with an AUC of 0.66
(Figure 4). Given the relatively low representation of
endometrioid (22 samples) and mucinous (15 samples) in
this cohort, the results of the analysis may be skewed and
further studies in these histotypes are clearly warranted.
Nonetheless, it is clear from this data that all three
markers – FRA, MSLN and MPF – are elevated in serous
ovarian cancer.
The serum levels of FRA, MSLN and MPF also dif-
fered by stage (Figure 5) and grade (Figure 6) of disease.
All three markers showed a significant correlation to
stage of disease and significantly higher levels in high
grade tumors relative to low grade tumors. While levels
of FRA and MSLN were also elevated in low grade tu-
mors relative to normal, MPF was not able to distinguish
low grade tumors from normal individuals. As shown in
Figures 5 and 6, FRA and MSLN were more similar in
diagnostic performance, as determined by ROC analyses,
than was MPF.
Biomarker performance in serous ovarian cancer cases
Based on the data presented above and the preponder-
ance of samples in our cohort from patients with serous
ovarian cancer, a more detailed analysis of marker distri-
butions and, importantly, comparisons to levels of
CA125 and HE4 was performed on a subset of 176 ser-
ous ovarian samples.
Correlations of biomarkers
Pairwise comparisons between FRA, MSLN, MPF,
CA125 and HE4 were made through use of Pearson’s
correlation coefficient (Table 3). FRA was weakly corre-
lated with CA125, HE4 and MPF, and moderately corre-
lated with MSLN. Like FRA, CA125 was moderately
correlated with MSLN and weakly correlated with the
other markers. Given the literature that MSLN interacts
with CA125 and may be involved in the metastatic
process, the relatively low correlation (r=0.53) of these
two markers in serum is somewhat surprising and may re-
flect different mechanisms by which these two proteins
A.  FRA B. FRA
E. MPF F. MPF
C. MSLN D. MSLN
Figure 4 Box plots of serum levels of A) FRA, C) MSLN and E) MPF in healthy controls and ovarian cancer patients by tumor type:
serous, endometrioid and mucinous. Boxes indicate the 25th to 75th percentiles. The horizontal lines within the boxes are the median serum
levels and the whiskers indicate the minimum and maximum values. P-values indicate statistical significance of differences between each group
and healthy controls. ROC curves showing the performance of B) FRA, D) MSLN and F) MPF serum biomarkers in discrimination of healthy
controls and ovarian cancer patients by tumor type: serous (blue line); endometrioid (red line); mucinous (green line).
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A. FRA B. FRA
C. MSLN D. MSLN
E . MPF F. MPF
Figure 5 Box plots of serum levels of A) FRA, C) MSLN and E) MPF in healthy controls and ovarian cancer patients by stage. Boxes
indicate the 25th to 75th percentiles. The horizontal lines within the boxes are the median serum levels and the whiskers indicate the minimum
and maximum values. P-values indicate statistical significance of differences between each group and healthy controls. ROC curves showing the
performance of B) FRA, D) MSLN and F) MPF serum biomarkers in discrimination of healthy controls and ovarian cancer patients by stage
(I, orange line; II, green line; III, red line; IV, blue line).
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Figure 6 Box plots of serum levels of A) FRA, C) MSLN and E) MPF in healthy controls and ovarian cancer patients by grade. Boxes
indicate the 25th to 75th percentiles. The horizontal lines within the boxes are the median serum levels and the whiskers indicate the minimum
and maximum values. P-values indicate statistical significance of differences between each group and healthy controls. ROC curves showing the
performance of B) FRA, D) MSLN and F) MPF serum biomarkers in discrimination of healthy controls and ovarian cancer patients by grade (low,
blue line; high, red line).
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entities derived from the same gene product, were only
correlated to r=0.66. This is most likely a reflection of the
fact that MPF is a soluble, proteolytic cleavage product ofthe gene product whereas MSLN is GPI-anchored and re-
quires additional processing to be released into the circu-
lation. Interestingly, the strongest correlation of markers
was for MPF and HE4 at r=0.83. The relatively low
Table 3 Pearson’s correlation coefficient between five
biomarkers
CA125 HE4 FRA MSLN MPF
CA125 1.000**** 0.299* 0.316* 0.527** 0.372*
HE4 0.299* 1.000**** 0.378** 0.627** 0.826***
FRA 0.316* 0.378* 1.000**** 0.467** 0.233*
MSLN 0.527** 0.627** 0.467** 1.000**** 0.659***
MPF 0.372* 0.826*** 0.233* 0.659** 1.000****





Figure 7 Box plots of serum levels of A) FRA, B) MSLN C) MPF D) CA1
patients. Boxes indicate the 25th to 75th percentiles. The horizontal lines
indicate the minimum and maximum values. P-values indicate statistical sig
ROC curves (FRA, blue line; MSLN, brown line; MPF, orange line; CA125, red
in discrimination of healthy controls and serous ovarian cancer patients.
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involvement in different and varied biological processes
in ovarian cancer and suggests their usefulness in a multi-
marker panel for improved discriminatory ability over
CA125 alone.Diagnostic performance in serous histology
The serum levels of FRA, MSLN, CA125 and HE4 readily
discriminated between serous ovarian cancer and control
serum samples (Figure 7), with p-values of <0.0001 forB. MSLN
F.
D. CA125
25 and E) HE4 in healthy controls and serous ovarian cancer
within the boxes are the median serum levels and the whiskers
nificance of differences between each group and healthy controls. F)
line; HE4, green line) showing the performance of serum biomarkers
A. FRA B. FRA




G. CA125 H. CA125
I. HE4
Figure 8 (See legend on next page.)
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Figure 8 Box plots of serum levels of A) FRA, C) MSLN, E) MPF G) CA125 and I) HE4 in healthy controls and serous ovarian cancer
patients by stage. Boxes indicate the 25th to 75th percentiles. The horizontal lines within the boxes are the median serum levels and the
whiskers indicate the minimum and maximum values. P-values indicate statistical significance of differences between each group and healthy
controls. ROC curves showing the performance of B) FRA, D) MSLN, F) MPF, H) CA125 and J) HE4 serum biomarkers in discrimination of healthy
controls and serous ovarian cancer patients by stage (I, orange line; II, green line; III, red line; IV, blue line).
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and MPF, respectively. ROC analyses resulted in AUCs, in
decreasing order, of 0.84 for CA125 (p<0.0001), 0.77 for
FRA (p<0.0001), 0.76 for MSLN (p=<0.0001), 0.76 for
HE4 (p=<0.0001), and 0.60 for MPF (p=0.0012) (Figure 7).
An assessment of each of the five biomarkers in the
cohort of 176 serous ovarian cancer samples relative to
stage of disease is presented in Figure 8. Each of the five
markers showed clear trends of increasing levels with in-
creasing stage of disease, although the level of signifi-
cance of these changes varied widely. All markers were
significantly increased in late stage disease, stages 3 and
4, relative to normal controls. CA125 and MSLN levels
were shown to be significantly different from normal
controls across all stages of disease.
Similarly, all five biomarkers were assessed relative to
grade of disease (Figure 9). As can be seen, all markers were
elevated and significantly different from normal controls in
high grade disease. FRA, MSLN and CA125 were also sig-
nificantly different in low grade disease. However, by ROC
analysis, FRA was not able to distinguish low grade disease
from normal controls (p=0.09) in this cohort. MSLN, MPF
and HE4 were only able to distinguish high grade disease
from normal controls, both by comparison of mean values
and by ROC analysis (Figure 9).Multi-marker logistic regression modeling
Given the diagnostic performance of the individual
markers, and in particular the relatively weak correlation
between markers, we applied logistic regression modeling
in an attempt to define a combination of markers that
would increase the diagnostic potential relative to the best
single performing marker, CA125. In the resulting model,
CA125 and MSLN were shown to increase the probability
of a diagnosis of ovarian cancer as their values increased,
whereas MPF showed the opposite effect. HE4 added
slightly to the performance of the model, but it was not sig-
nificant and therefore not included. The best model in-
cluded CA125, FRA, MSLN and MPF and as can be seen
in the ROC analysis presented in Figure 10, the ability of
this four-marker panel to discriminate between ovarian
cancer patients and healthy women was significantly im-
proved (p=0.003) over that of CA125 alone: logistic
regression (LR) AUC=0.91, p<0.0001; CA125 AUC=0.84,
p<0.0001. The presented combination of markers may serveas a multi-marker panel to aid in the early diagnosis of
EOC, particularly for the serous histology.Discussion
CA125, first introduced in the mid-1980s, remains the
gold standard with respect to detection and monitoring of
ovarian cancer. In recent years other markers, in particular
HE4 have gained acceptance, with somewhat limited util-
ity [64-67], and some work has been reported on combin-
ing CA125 and HE4 to further increase the diagnostic
application of these serum markers [2,9,11,15]. Several
other markers of ovarian cancer, including MSLN and, to
a lesser extent, MPF have been described [1,15,23,30-33].
However, there are no reports to our knowledge that have
performed as comprehensive an analysis of all of these
markers as presented here.
FRA has been the subject of intense research as a poten-
tial therapeutic target in the last several years primarily be-
cause of its highly restricted expression profile in normal
tissues [40] and high levels expression in a number of can-
cers of epithelial origin, including serous ovarian cancer
[39-52,54-58,68,69]. Several late-stage clinical trials in ovar-
ian cancer and non-small cell lung adenocarcinoma are
presently on-going [68-70]. It is important, therefore, to de-
velop robust assays for FRA both in tissue and in the circu-
lation. With this in mind, the present work describes, for
the first time, a specific and sensitive ECL-based assay using
novel MAb reagents for the detection of FRA in serum,
plasma and urine, allowing a comprehensive analysis of its
diagnostic potential. Further, the potential clinical utility of
serum MPF is not well documented. We therefore chose to
develop a similar ECL-based assay for MPF for comparative
studies not only to FRA, but to other more accepted
markers of ovarian cancer – CA125, MSLN and HE4.
The described assays showed excellent limits of detection
in the low pg/mL range and wide dynamic ranges up to at
least 5000 pg/mL. From a practical point of view, such as-
says will require less in the way of repeat sample testing
due to high marker levels. Importantly, FRA, MSLN and
MPF were all shown to distribute equivalently between
serum and plasma allowing flexibility in the choice of sam-
ple matrix. On the other hand, markers such as osteopontin
are known to distribute more into the plasma fraction,
restricting the sample type. FRA, MSLN and MPF were all
shown to be detectable in urine samples from both healthy
I. HE4 J.  HE4
G. CA125 H.  CA125
E. MPF F.  MPF
A. FRA B.  FRA
C. MSLN D. MSLN
Figure 9 (See legend on next page.)
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Figure 9 Box plots of serum levels of A) FRA, C) MSLN and E) MPF G) CA125 and I) HE4in healthy controls and serous ovarian cancer
patients by grade. Boxes indicate the 25th to 75th percentiles. The horizontal lines within the boxes are the median serum levels and the
whiskers indicate the minimum and maximum values. P-values indicate statistical significance of differences between each group and healthy
controls. ROC curves showing the performance of B) FRA, D) MSLN, F) MPF, H) CA125 and J) HE4 serum biomarkers in discrimination of healthy
controls and serous ovarian cancer patients by grade (low, blue line; high, red line).
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utility of MSLN measurement in urine for ovarian cancer
has previously been described. In view of the ease of urine
sample collection, the clinical utility of diagnostic assays
assessing levels of FRA and MPF in urine is evident.
The data presented here demonstrates that for each of
the markers analyzed – CA125, HE4, MSLN, MPF and
FRA – there was a preferential expression in the serous
histotype. Recent work from our laboratory using immu-
nohistochemical techniques for the detection of FRA,
have shown a similar preferential expression in serous
carcinomas [59]. Taken together, these data support the
current understanding of the origin of the various
histotypes of ovarian cancer with the most common ser-
ous histotype deriving from tubal fimbriae [71]. Indeed,
we recently demonstrated that FRA is highly expressed
in tubal epithelium while normal ovary epithelium is de-
void of FRA expression [59].
The analyzed markers showed low to moderate corre-
lations with each other. Surprisingly, CA125 and MSLN
were not highly correlated even though CA125 has
been described to be the ligand for MSLN and to be in-
volved in the metastatic process in ovarian cancer.
More surprisingly, perhaps, is the moderate correlation
between MSLN and MPF since these molecules shouldFigure 10 Performance of multi-marker panels for the
discrimination of ovarian cancer patients (n=176) from healthy
controls (n=20). ROC showing the performance of a four-biomarker
panel, consisting of CA125, FRA, MSLN and MPF) in differentiating all
ovarian cancer patients from healthy controls. The AUCs of the
panel (AUC=0.91) was significantly improved over that of CA125
alone (AUC=0.84).be present in a 1:1 molar ratio given the fact that they
derive from the same RNA and that MPF is simply a
proteolytic product of the initial gene product. How-
ever, since MSLN is a GPI-anchored protein whereas
MPF is soluble, these findings, as with the correlations
of the other described markers, most likely reflect a
combination of the route by which the markers enter
the circulation and, importantly, the clearance from the
circulation. For example, while MSLN, MPF and FRA
are detectable in urine, CA125 is not. Further, FRA has
been shown to bind to megalin, both in the kidney and
liver and, as such, is removed from circulation [72].
The glomerular filtration of at least some of these
markers [32,35,73,74], as well as the potential for other
clearance mechanisms, has been described previously
and may be a confounding factor in the measurement
and application of these markers. Ultimately, this may
explain the performance of CA125 as the single best
marker for ovarian cancer.
However, as described herein, combining markers
with CA125 does increase the diagnostic performance
of the marker panel over CA125 alone, allowing for the
development of a multi-marker panel that increases the
sensitivity of detection of early stage disease while
retaining specificity, the ultimate goal in ovarian cancer
diagnosis.Conclusions
CA125 remains the best single biomarker for diagnosis
and monitoring of ovarian cancer. However, additional
markers are sought for use independently or in combin-
ation with CA125 to improve the sensitivity for ovarian
cancer detection whilst retaining specificity. The current
study presents data on the utility of a novel marker, folate
receptor alpha, FRA; with respect to discrimination be-
tween ovarian cancer, for example, the serous histotype,
and normal controls. Further, data was presented for add-
itional markers including MSLN and MPF and the use of
these markers in a multi-marker panel that outperforms
CA125 alone.
Development of additional markers for use either indi-
vidually or in a panel for the diagnosis or detection of
ovarian cancer, especially early stage disease, is critical.
The novel ECL assays described herein provide a power-
ful tool for such development.
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